Suppliers and packagers for CLONIDINE

CLONIDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Labs Ut Inc	CLONIDINE	clonidine	SYSTEM;TRANSDERMAL	090873	ANDA	Actavis Pharma, Inc.	0591-3508-04	4 POUCH in 1 CARTON (0591-3508-04) / 1 PATCH in 1 POUCH (0591-3508-54) / 7 d in 1 PATCH	2014-05-06
Actavis Labs Ut Inc	CLONIDINE	clonidine	SYSTEM;TRANSDERMAL	090873	ANDA	Actavis Pharma, Inc.	0591-3509-04	4 POUCH in 1 CARTON (0591-3509-04) / 1 PATCH in 1 POUCH (0591-3509-54) / 7 d in 1 PATCH	2014-05-06
Actavis Labs Ut Inc	CLONIDINE	clonidine	SYSTEM;TRANSDERMAL	090873	ANDA	Actavis Pharma, Inc.	0591-3510-04	4 POUCH in 1 CARTON (0591-3510-04) / 1 PATCH in 1 POUCH (0591-3510-54) / 7 d in 1 PATCH	2014-05-06

Clonidine API Suppliers and Market Dynamics

Last updated: February 19, 2026

Clonidine, a centrally acting alpha-2 adrenergic agonist, is a pharmaceutical ingredient used to treat hypertension, ADHD, and withdrawal symptoms. This report analyzes key suppliers of Clonidine Active Pharmaceutical Ingredient (API) and relevant market factors influencing its production and distribution.

Who are the Major Clonidine API Manufacturers?

The global supply chain for Clonidine API is characterized by a mix of established generic manufacturers and specialized chemical synthesis companies. Key players include:

• Centaur Pharmaceuticals Pvt. Ltd.: An Indian pharmaceutical company known for its production of various APIs, including clonidine. They operate multiple manufacturing facilities compliant with international regulatory standards.
• Divi’s Laboratories Limited: Another prominent Indian API manufacturer with significant global market share in several therapeutic areas. Divi’s has a strong focus on process chemistry and scale-up for complex molecules, including clonidine.
• Granada Corporation: A U.S.-based company that has historically supplied pharmaceutical ingredients. Their involvement in clonidine API production targets specific markets and regulatory requirements.
• Hubei Bio-Union Pharmaceutical Co., Ltd.: A Chinese manufacturer that contributes to the global supply of clonidine API. Chinese manufacturers are significant players in the broader API market due to cost competitiveness and large-scale production capacities.
• Neuland Laboratories Limited: An Indian pharmaceutical company that manufactures and supplies a wide range of APIs, including clonidine, for global markets. They emphasize regulatory compliance and quality control.
• Taj Pharmaceuticals Ltd.: An Indian pharmaceutical company with diverse API manufacturing capabilities. Taj Pharmaceuticals supplies clonidine API to various international markets.
• Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva also manufactures and supplies APIs for its own formulations and for sale to other pharmaceutical companies. Clonidine is among their API offerings.
• Zhejiang NHU Co., Ltd.: A major Chinese chemical and pharmaceutical company that produces a broad spectrum of vitamins, food additives, and APIs. NHU is a significant supplier of various APIs to the global market, including clonidine.

What are the Key Manufacturing and Regulatory Considerations for Clonidine API?

Clonidine API manufacturing is subject to stringent quality control and regulatory oversight to ensure patient safety and product efficacy.

• Good Manufacturing Practices (GMP): All manufacturers must adhere to GMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national agencies. This includes rigorous process validation, impurity profiling, and stability testing.
• Impurity Profiling: Identifying and controlling process-related impurities and degradation products is critical. For clonidine, potential impurities can arise from the synthetic route, such as starting materials, intermediates, or by-products of side reactions. Regulatory agencies require manufacturers to establish strict limits for known and unknown impurities.
• Regulatory Filings: Manufacturers seeking to supply clonidine API to regulated markets must submit Drug Master Files (DMFs) or equivalent dossiers to regulatory authorities. These filings detail the manufacturing process, controls, and specifications. FDA DMFs, for instance, allow drug product manufacturers to reference the API information without disclosing proprietary details.
• Supply Chain Security: Ensuring the integrity of the clonidine API supply chain from raw material sourcing to final product delivery is paramount. This involves supplier qualification, auditing, and robust inventory management.
• Quality Standards: Clonidine API must meet pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs specify tests for identity, assay, purity, and other quality attributes.

What Factors Influence Clonidine API Pricing and Availability?

The cost and consistent availability of clonidine API are affected by several market dynamics:

• Raw Material Costs: The price and availability of key chemical precursors used in clonidine synthesis directly impact API production costs. Fluctuations in the prices of these commodities, often influenced by global supply and demand, geopolitical factors, and environmental regulations affecting their production, can lead to price volatility for clonidine API.
• Manufacturing Capacity and Utilization: The overall global manufacturing capacity for clonidine API, balanced against the demand from finished drug product manufacturers, determines market tightness. High utilization rates in key manufacturing regions can lead to price increases, while overcapacity may result in competitive pricing.
• Regulatory Compliance Costs: Investments required to meet evolving GMP standards, environmental regulations, and quality control requirements add to the cost of API production. Companies that maintain high compliance standards may incur higher operational costs but also offer greater reliability to their customers.
• Geopolitical and Trade Policies: Trade agreements, tariffs, and geopolitical stability in major API manufacturing regions (particularly China and India) can influence the cost and flow of clonidine API. Disruptions to shipping or trade routes can impact availability and price.
• Demand Fluctuations: Changes in the prevalence of conditions treated by clonidine (e.g., hypertension, ADHD) and the market penetration of generic vs. branded clonidine products can affect API demand. Increased generic competition often leads to pressure on API prices.
• Intellectual Property Landscape: While clonidine itself is a well-established molecule with expired primary patents, any new synthetic routes or polymorphs with patent protection could influence market entry for new suppliers, although this is less common for older generic APIs.

What is the Projected Market Outlook for Clonidine API?

The market for clonidine API is expected to remain stable, driven by its established therapeutic uses.

• Steady Demand: Clonidine's continued use in treating hypertension, ADHD, and withdrawal symptoms ensures a consistent baseline demand for the API. Its efficacy and long history of use contribute to its enduring market presence.
• Generic Market Dominance: The clonidine market is largely dominated by generic formulations. This competitive landscape puts downward pressure on API pricing but sustains demand from multiple generic drug manufacturers.
• Growth in Developing Markets: As healthcare access expands in developing countries, the demand for essential medicines like clonidine is projected to grow, offering potential market expansion opportunities for API suppliers.
• Focus on Quality and Reliability: With increasing global scrutiny on pharmaceutical supply chains, there is a continued emphasis on sourcing API from manufacturers with robust quality systems and a proven track record of regulatory compliance. Suppliers that can consistently meet these demands are well-positioned.
• Competition from Alternative Therapies: While clonidine remains a valuable treatment option, the development of newer therapeutic agents for hypertension and ADHD could, over the long term, influence market share and API demand, although significant shifts are not immediately anticipated given clonidine's established role and cost-effectiveness.

Key Takeaways

• The clonidine API market is served by a global network of manufacturers, with significant presence in India and China.
• Regulatory compliance (GMP, impurity profiling, DMF filings) is a critical barrier to entry and a key differentiator for API suppliers.
• API pricing and availability are influenced by raw material costs, manufacturing capacity, geopolitical factors, and demand from generic drug producers.
• The clonidine API market is projected for stable demand, driven by its established therapeutic uses, with continued competition and a focus on supply chain reliability.

Frequently Asked Questions

1. What are the primary chemical synthesis routes for Clonidine API? Clonidine is typically synthesized through routes involving imidazoline intermediates. A common method involves the reaction of 2,6-dichloroaniline with cyanogen bromide to form 2-amino-2,6-dichlorobenzonitrile, followed by reaction with ethylenediamine or its derivatives under specific conditions to yield clonidine. Variations in the choice of reagents and reaction conditions can influence yield and impurity profiles.

2. How does the regulatory status of API suppliers in India and China affect global clonidine supply? Manufacturers in India and China are major global suppliers of clonidine API. Their adherence to GMP standards and successful inspections by regulatory bodies like the FDA and EMA are crucial. Any regulatory actions against these facilities, such as import alerts or warning letters, can significantly disrupt the global supply chain and necessitate sourcing from alternative, compliant manufacturers, potentially impacting pricing and lead times.

3. What are the common impurity concerns for Clonidine API, and how are they managed? Common impurities in clonidine API can include unreacted starting materials (e.g., 2,6-dichloroaniline), intermediate by-products, or degradation products formed during synthesis or storage. For example, related substances such as 2-amino-2,6-dichlorobenzonitrile or dimers of guanidine derivatives could be present. Manufacturers manage these impurities through rigorous process control, optimization of reaction conditions, use of high-purity starting materials, and validated purification steps. Analytical methods like High-Performance Liquid Chromatography (HPLC) are used for routine impurity testing against established specifications.

4. Are there any specific market trends or challenges unique to the Clonidine API supply for ADHD treatment compared to hypertension? While the API itself is the same, the demand drivers can vary. The use of clonidine for ADHD is often as a second-line or adjunct therapy, sometimes in extended-release formulations. This might lead to specific purity requirements for certain formulations or a demand for API suitable for extended-release technology. Challenges could include the need for highly consistent particle size distribution or specific polymorphic forms, depending on the final dosage form requirements for ADHD medications.

5. What is the typical shelf-life of Clonidine API, and what factors influence its stability? The typical shelf-life for clonidine API, when stored under recommended conditions (e.g., protected from light and moisture in well-sealed containers), is generally between 2 to 5 years. Its stability is influenced by factors such as exposure to light, heat, and humidity, which can promote degradation reactions. Manufacturers conduct stability studies according to International Council for Harmonisation (ICH) guidelines to determine appropriate retest dates or expiry dates and storage conditions.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files [2] European Medicines Agency. (n.d.). Guidance on GMP. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/compliance-research-and-development/good-manufacturing-practice-compliance [3] United States Pharmacopeia. (n.d.). USP General Chapters. [4] European Pharmacopoeia. (n.d.). Ph. Eur. Home. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/